Alnylam gets good news on RNAi treatment; Northwestern looks at getting nanotech into cancer nuclei;

 @DamianFierce: Using self-assembling DNA tubes, Harvard researchers plan to effectively deliver drugs to cells. News | Follow @DamianFierce

> Alnylam ($ALNY) is reporting positive Phase I results for its RNAi therapy designed to treat transthyretin-mediated amyloidoisis. Release

> A NeuroSigma subsidiary, NSVascular, has bought the patents for thin-film nitinol fabrication with an eye on its drug delivery applications. News

> Getting nanocarriers to tumors is one thing; getting them inside to deliver their payloads is another. Researchers at Northwestern University are working to get nanoparticles into the nuclei of cancer cells. Article

> Pearl Therapeutics is preparing to present positive Phase II results for PT003, a novel-formulation COPD treatment. Story

> Pulmatrix has revealed the results of preclinical tests on iSperse, an inhaled drug delivery platform that demonstrated its ability to deliver antibiotics, antibodies and other macromolecules. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.